SAN FRANCISCO, Feb. 16, 2015 /PRNewswire/ -- Maverix Biomics,
Inc. today announced at the 23rd International Molecular
Medicine Tri-Conference (Tricon) in San
Francisco, CA that the company has signed a strategic
cooperation agreement with Elsevier, a world-leading provider of
scientific, technical and medical information products and
services, to streamline the interpretation of raw
next-generation sequencing (NGS) data to reveal new insights and to
assist with critical decision making. The Maverix Analytic Platform
will complement Pathway Studio's sample-to-insight workflow and
incorporation of biological data from Elsevier's biology
journals by providing easy, push-button data analysis, which
is now integrated with Elsevier's Pathway Studio research
solution for biologists. Financial terms were
not disclosed.
The combination of the Maverix Analytic Platform and Elsevier's
Pathway Studio is an integrated solution that starts with raw NGS
data and quickly produces genome alignment, quality metrics,
variant and expression analysis, and the ability to analyze and
visualize disease mechanisms derived from published scientific
data.
Today at Tricon, Maverix Biomics' Chief Scientific Officer
Todd Lowe is chairing a keynote
session entitled "Advances in Genome and Transcriptome Analysis,"
which will address advances in areas such as single cell analysis
and CRISPR genome editing, as well as the use of DNA-seq variant
analysis and RNA-seq expression analysis in fields such as
clinical research and diagnostics as well as the workflow
challenges in these settings.
"This collaboration gives more value to our customers – not only
can they use the two great tools our companies produce, but they
can now save time by seamlessly using them together. This reduces
their workload, reduces complexity and increases accuracy of their
analysis," said Jaqui Hodgkinson, VP
Product Development of Elsevier Life Sciences Solutions.
"We are pleased to be able to offer the Maverix Analytic
Platform directly integrated with the Elsevier's Pathway Studio
solution for researchers," said Dave
Mandelkern, Maverix president and co-founder. "The combined
offering will help researchers unravel hidden biology in
experimental data or literature-based evidence, which will be
especially useful in building and visualizing disease models."
About Pathway Studio®
Pathway Studio is integrated data mining and visualization
software with a high-quality, comprehensive knowledgebase produced
by applying Elsevier's proprietary text-mining technology to a
large corpus of biological literature. Pathway Studio allows
organizations and researchers to rapidly connect relevant
biological facts and relationships, integrate and interpret
experimental data, and visualize the results. Pathway Studio is
used for defining and testing in silico-based hypotheses
across a wide range of disciplines including mechanistic modeling
of disease, drug action and toxicity, target discovery and
validation, biomarker discovery, cellular and network pathway
building, protein-protein interactions and many more.
Pathway Studio is offered in configurations that scale to
support individual researchers and global corporations with access
to custom and domain-specific knowledgebases. For more information,
visit the Pathway Studio website:
http://www.elsevier.com/online-tools/pathway-studio
About Elsevier
Elsevier is a world-leading provider of information solutions
that enhance the performance of science, health, and technology
professionals, empowering them to make better decisions, deliver
better care, and sometimes make groundbreaking discoveries that
advance the boundaries of knowledge and human progress. Elsevier
provides web-based, digital solutions — among them ScienceDirect,
Scopus, Elsevier Research Intelligence, and ClinicalKey—and
publishes over 2,200 journals, including The Lancet and
Cell, and over 33,000 book titles, including a number of
iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading
provider of professional information solutions in the Science,
Medical, Legal and Risk and Business sectors, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols
are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).
About the Maverix Analytic Platform
The Maverix Analytic Platform is a cloud-based solution designed
for use directly by life sciences researchers who may not have
software or bioinformatics expertise. It leverages proven
open-source algorithms and applications developed at leading
academic and research centers. After loading sequence data from any
organism (human, animal, plant, or microbe), researchers are able
to immediately perform analyses with reliable, scientifically
vetted configurations, as cited in peer-reviewed journal
publications. Visualization is provided through a variety of
integrated graphical tools, including a private, secure version of
the UCSC Genome Browser, the world's most widely used genome
browser.
About Maverix Biomics
Based in San Mateo, CA and
backed by leading venture capital firms and Silicon Valley
investors, Maverix Biomics, Inc. provides researchers with a
cloud-based platform to manage, analyze, and visualize genomic
data, build Communities of Discovery, and place their data in
context with the latest public data from the full spectrum of life,
including human, plant, animal, or microbial organisms. For more
information, visit www.maverixbio.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/maverix-biomics-and-elsevier-sign-cooperation-agreement-300036470.html
SOURCE Maverix Biomics